Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
Schizophrenia has been associated with aberrant blood levels of inflammatory markers. However, patients with comorbid illicit drug use have been inadequately studied with respect to immune function. Furthermore, associations between inflammatory markers, psychopathology, and cognition have been inco...
Saved in:
| Published in | Schizophrenia research Vol. 195; pp. 275 - 282 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.05.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Schizophrenia has been associated with aberrant blood levels of inflammatory markers. However, patients with comorbid illicit drug use have been inadequately studied with respect to immune function. Furthermore, associations between inflammatory markers, psychopathology, and cognition have been inconsistently considered. We investigated relationships between inflammatory markers, comorbid marijuana and cocaine use, and psychopathology and cognition in patients with schizophrenia.
For subjects with available fasting data from the baseline visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, inflammatory markers were investigated as predictors of psychopathology and cognition in patients with and without comorbid marijuana or cocaine use, using linear regression models controlling for potential confounding factors.
Compared to subjects with a negative urine drug screen (UDS), marijuana use was a predictor of higher lymphocytes and E-selectin, and lower leptin (p≤0.04 for each); cocaine use was a predictor of higher adiponectin (p=0.04). In subjects with marijuana use, lower WBC and higher IL-6 were predictors of higher PANSS total score (p<0.05 for each). In subjects with cocaine use, lower total and differential WBC were predictors of higher PANSS total score (p<0.04 for each). In younger, non-obese subjects with a negative UDS, higher monocytes and IL-6 were predictors of PANSS total score (p<0.04 for each).
Our findings provide additional evidence that inflammation may be associated with psychopathology and cognition in some patients with schizophrenia. Furthermore, there is preliminary evidence for differential effects of comorbid marijuana and cocaine use on these relationships. |
|---|---|
| AbstractList | Schizophrenia has been associated with aberrant blood levels of inflammatory markers. However, patients with comorbid illicit drug use have been inadequately studied with respect to immune function. Furthermore, associations between inflammatory markers, psychopathology, and cognition have been inconsistently considered. We investigated relationships between inflammatory markers, comorbid marijuana and cocaine use, and psychopathology and cognition in patients with schizophrenia.
For subjects with available fasting data from the baseline visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, inflammatory markers were investigated as predictors of psychopathology and cognition in patients with and without comorbid marijuana or cocaine use, using linear regression models controlling for potential confounding factors.
Compared to subjects with a negative urine drug screen (UDS), marijuana use was a predictor of higher lymphocytes and E-selectin, and lower leptin (p≤0.04 for each); cocaine use was a predictor of higher adiponectin (p=0.04). In subjects with marijuana use, lower WBC and higher IL-6 were predictors of higher PANSS total score (p<0.05 for each). In subjects with cocaine use, lower total and differential WBC were predictors of higher PANSS total score (p<0.04 for each). In younger, non-obese subjects with a negative UDS, higher monocytes and IL-6 were predictors of PANSS total score (p<0.04 for each).
Our findings provide additional evidence that inflammation may be associated with psychopathology and cognition in some patients with schizophrenia. Furthermore, there is preliminary evidence for differential effects of comorbid marijuana and cocaine use on these relationships. INTRODUCTIONSchizophrenia has been associated with aberrant blood levels of inflammatory markers. However, patients with comorbid illicit drug use have been inadequately studied with respect to immune function. Furthermore, associations between inflammatory markers, psychopathology, and cognition have been inconsistently considered. We investigated relationships between inflammatory markers, comorbid marijuana and cocaine use, and psychopathology and cognition in patients with schizophrenia.METHODFor subjects with available fasting data from the baseline visit of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, inflammatory markers were investigated as predictors of psychopathology and cognition in patients with and without comorbid marijuana or cocaine use, using linear regression models controlling for potential confounding factors.RESULTSCompared to subjects with a negative urine drug screen (UDS), marijuana use was a predictor of higher lymphocytes and E-selectin, and lower leptin (p≤0.04 for each); cocaine use was a predictor of higher adiponectin (p=0.04). In subjects with marijuana use, lower WBC and higher IL-6 were predictors of higher PANSS total score (p<0.05 for each). In subjects with cocaine use, lower total and differential WBC were predictors of higher PANSS total score (p<0.04 for each). In younger, non-obese subjects with a negative UDS, higher monocytes and IL-6 were predictors of PANSS total score (p<0.04 for each).CONCLUSIONSOur findings provide additional evidence that inflammation may be associated with psychopathology and cognition in some patients with schizophrenia. Furthermore, there is preliminary evidence for differential effects of comorbid marijuana and cocaine use on these relationships. |
| Author | Miller, Brian J. McEvoy, Joseph P. Buckley, Peter F. |
| Author_xml | – sequence: 1 givenname: Brian J. surname: Miller fullname: Miller, Brian J. email: brmiller@augusta.edu organization: Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA, United States – sequence: 2 givenname: Peter F. surname: Buckley fullname: Buckley, Peter F. organization: School of Medicine, Virginia Commonwealth University, Richmond, VA, United States – sequence: 3 givenname: Joseph P. surname: McEvoy fullname: McEvoy, Joseph P. organization: Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28843438$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1uFDEQhC0URDaBN0DIRw67g3_mzxckFEESKRIXOFseu53xasYebE-kfYq8Ml4mcOTUaumranXVFbrwwQNC7ympKKHtp2OV9BghVYzQriJ9RVj3Cu1o0_EDa4i4QDsiGDkI0daX6CqlIyGENqR7gy5Z39e85v0OPd97O6l5VtkFv8dpHVJWXgNeE-zxkk56DIvKY5jC42mPlTdYh0fvzjh2Hi-jSoApDhbnEbCenHdaTQXMblNnp3GOTk3pDDmfIT6B_6MHa0FnV1ZICae8mtNb9NoWFN69zGv089vXHzd3h4fvt_c3Xx4OumZ9PmjRKT5Y3fBW8EYMFHqtjNBdV1tjGyZY0zXCNP3Ahq4jxPaMWWNor1vg7dDya_Rx811i-LVCynJ2ScM0KQ9hTZIKzhknrWAFrTdUx5BSBCuX6GYVT5ISea5CHuVWhTxXIUkvSxVF9uHlwjrMYP6J_mZfgM8bAOXPJwexuDgo2RsXSyzSBPf_C78BC0uhtQ |
| CitedBy_id | crossref_primary_10_1016_j_pnpbp_2019_109835 crossref_primary_10_1080_15504263_2021_2013697 crossref_primary_10_1111_acps_13140 crossref_primary_10_1097_NMD_0000000000001019 crossref_primary_10_1111_eip_12859 crossref_primary_10_1016_j_bbr_2021_113229 crossref_primary_10_1017_neu_2023_24 crossref_primary_10_1080_08039488_2019_1688389 crossref_primary_10_1016_j_comppsych_2023_152435 crossref_primary_10_1016_j_schres_2020_05_036 crossref_primary_10_3390_pathogens12111333 crossref_primary_10_1007_s00406_020_01134_x crossref_primary_10_1016_j_sjbs_2021_06_056 crossref_primary_10_1016_j_psychres_2020_113380 crossref_primary_10_1016_j_schres_2018_12_017 crossref_primary_10_3928_00485713_20181107_02 crossref_primary_10_1093_ijnp_pyaa097 crossref_primary_10_1016_j_psychres_2021_114195 crossref_primary_10_1016_j_bbr_2020_113101 crossref_primary_10_1016_j_pmip_2023_100106 crossref_primary_10_1016_j_bbi_2023_08_001 crossref_primary_10_1017_S0033291721000726 crossref_primary_10_1002_wps_20624 |
| Cites_doi | 10.1002/hup.1251 10.1007/s00406-004-0478-1 10.1017/S1355617714000691 10.1016/j.bbi.2009.04.005 10.1210/jc.2002-020804 10.1016/j.jad.2015.11.017 10.1111/adb.12156 10.1016/j.biopsych.2011.04.013 10.1038/mp.2016.3 10.1038/npp.2016.211 10.1001/jama.289.15.1929-a 10.1016/j.biopsych.2009.06.005 10.1016/j.schres.2015.10.001 10.1038/nature13595 10.1016/j.neulet.2016.06.023 10.1093/schbul/sbt070 10.1124/jpet.106.112797 10.1007/BF02900219 10.4088/JCP.09m05117yel 10.1038/sj.npp.1301072 10.1177/1535370214537747 10.1038/nature16549 10.1016/j.schres.2012.01.016 10.1016/0006-8993(94)90006-X 10.1176/appi.ajp.2009.08010031 10.1016/j.bbi.2014.01.018 10.1016/j.intimp.2005.10.004 10.1016/S0006-8993(99)02063-6 10.1016/j.pnpbp.2013.06.011 10.1016/j.pnpbp.2011.05.011 10.3109/13651501.2012.687452 10.1016/j.schres.2013.10.019 10.1016/j.drugalcdep.2014.04.011 10.1016/0920-9964(95)00068-2 10.1176/appi.ajp.2013.13010086 10.1176/appi.ajp.2009.09030361 10.1186/s12888-016-0866-x 10.1056/NEJMoa051688 10.1111/j.1471-4159.2009.06325.x 10.1007/s00213-003-1750-1 10.1038/nature08192 10.1093/schbul/sbt139 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier B.V. Copyright © 2017 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2017 Elsevier B.V. – notice: Copyright © 2017 Elsevier B.V. All rights reserved. |
| DBID | NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.schres.2017.08.027 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1573-2509 |
| EndPage | 282 |
| ExternalDocumentID | 10_1016_j_schres_2017_08_027 28843438 S0920996417305030 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AACTN AADFP AADPK AAEDT AAEDW AAGJA AAGUQ AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXLA AAXUO ABBQC ABCQJ ABFNM ABIVO ABJNI ABLVK ABMAC ABMZM ABOYX ABXDB ABYKQ ACDAQ ACGFS ACHQT ACIUM ACRLP ACXNI ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AFYLN AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM LCYCR M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- AAXKI AFJKZ AKRWK NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c428t-c97a3bfc5369359b1e8cad9c774fdf52925759d58b2b7700f822fdd18c6e36b63 |
| IEDL.DBID | AIKHN |
| ISSN | 0920-9964 |
| IngestDate | Sun Sep 29 07:35:40 EDT 2024 Thu Sep 26 17:38:16 EDT 2024 Wed Oct 16 00:59:54 EDT 2024 Fri Feb 23 02:32:21 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Schizophrenia Marijuana Inflammation Cocaine Cognition Psychopathology |
| Language | English |
| License | Copyright © 2017 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c428t-c97a3bfc5369359b1e8cad9c774fdf52925759d58b2b7700f822fdd18c6e36b63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 28843438 |
| PQID | 1933230692 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1933230692 crossref_primary_10_1016_j_schres_2017_08_027 pubmed_primary_28843438 elsevier_sciencedirect_doi_10_1016_j_schres_2017_08_027 |
| PublicationCentury | 2000 |
| PublicationDate | May 2018 2018-May 2018-05-00 20180501 |
| PublicationDateYYYYMMDD | 2018-05-01 |
| PublicationDate_xml | – month: 05 year: 2018 text: May 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Schizophrenia research |
| PublicationTitleAlternate | Schizophr Res |
| PublicationYear | 2018 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Muller, Ulmschneider, Scheppach (bb0150) 2004; 254 Igue, Potvin, Ramatoulaye, Stip, Bouchard, Lipp, Gendron, Kouassi (bb0075) 2011; 35 Pae, Yoon, Kim, Kim, Park, Lee, Lee, Lee, Paik (bb0170) 2006; 6 Keen, Turner (bb0090) 2014; 20 Fox, D'Sa, Kimmerling (bb0045) 2012; 27 Meyer, McEvoy, Davis, Goff, Nasrallah, Davis, Hsiao, Swartz, Stroup, Lieberman (bb0125) 2009; 66 Martin, Kem, Freedman (bb0120) 2004; 174 Sommer, van Westrhenen, Begemann, de Witte, Leucht, Kahn (bb0200) 2014; 40 Zalcman, Savina, Wise (bb0225) 1999; 847 Gaspar, Bustamante, Silva (bb0060) 2009; 111 Miller, Goldsmith (bb0130) 2017; 42 Sekar, Bialas, de Rivera (bb0190) 2016; 530 Pacifi, Zuccaro, Pchini (bb0165) 2003; 289 Irwin, Olmos, Wang (bb0080) 2007; 320 San, Bernardo, Gómez, Peña (bb0180) 2013; 17 Benros, Pedersen, Rasmussen, Eaton, Nordentoft, Mortensen (bb0010) 2014; 171 Fernandez-Egea, Socriels, Theegala, Giro, Ozanne, Burling, Jones (bb0035) 2013; 46 Laan, Grobbee, Selten (bb0105) 2010; 71 Frydecka, Misiak, Pawlak-Adamska, Karabon, Tomkiewicz, Sedlaczek (bb0055) 2015; 262 Miller, Buckley, Seabolt, Mellor, Kirkpatrick (bb0135) 2011; 70 Brown, Derkits (bb0015) 2010; 167 van Dijk, Koeter, Hijman, Kahn, van den Brink (bb0215) 2012; 137 Levandowski, Bensfeld Hess, Grassi-Oliveira (bb0110) 2016; 628 Miller, Mellor, Buckley (bb0140) 2013; 39 Shi, Levinson, Duan (bb0195) 2009; 460 O'Connor (bb0160) 2009; 23 Chase, Cone, Rosen (bb0020) 2016; 16 Fond, Godin, Brunel (bb0040) 2016; 19 Goldsmith, Rapaport, Miller (bb0065) 2016; 21 Lieberman, Stroup, McEvoy, Swartz, Rosenheck, Perkins (bb2015) 2005; 353 Keefe, Bilder, Harvey, Davis, Palmer, Gold, Meltzer, Green, Miller, Canive, Adler, Manschreck, Swartz, Rosenheck, Perkins, Walker, Stroup, McEvoy, Lieberman (bb0085) 2006; 31 Araos, Pedraz, Serrano (bb0005) 2015; 20 Nitta, Kishimoto, Müller, Weiser, Davidson, Kane (bb0155) 2013; 39 Halpern, Sholar, Glowacki, Mello, Mendelson, Siegel (bb0070) 2003; 88 Mori, McEvoy, Miller (bb0145) 2015; 169 Keen, Pereira, Latimer (bb0100) 2014; 140 Zalcman, Green-Johnson, Murray (bb0220) 1994; 643 Marasco, Goodwin, Winder (bb0115) 2014; 239 Clarke, Tanskanen, Huttunen, Whittaker, Cannon (bb0025) 2009; 166 Dimitrov, Lee, Yantis (bb0030) 2013; 151 Pedraz, Araos, Garcia-Marchena (bb0175) 2015; 6 Schizophrenia Working Group of the Psychiatric Genomics Consortium (bb0185) 2014; 511 Suarez-Pinilla, Lopel-Gil, Crespo-Facorro (bb0205) 2014; 40 Frommberger, Bauer, Haselbauer, Fraulin, Riemann, Berger (bb0050) 1997; 247 Swofford, Kasckow, Scheller-Gilkey, Inderbitzin (bb0210) 1996; 20 Keen, Turner (bb0095) 2015; 20 Dimitrov (10.1016/j.schres.2017.08.027_bb0030) 2013; 151 Sommer (10.1016/j.schres.2017.08.027_bb0200) 2014; 40 Keefe (10.1016/j.schres.2017.08.027_bb0085) 2006; 31 Chase (10.1016/j.schres.2017.08.027_bb0020) 2016; 16 Frommberger (10.1016/j.schres.2017.08.027_bb0050) 1997; 247 Irwin (10.1016/j.schres.2017.08.027_bb0080) 2007; 320 San (10.1016/j.schres.2017.08.027_bb0180) 2013; 17 Fond (10.1016/j.schres.2017.08.027_bb0040) 2016; 19 Brown (10.1016/j.schres.2017.08.027_bb0015) 2010; 167 Keen (10.1016/j.schres.2017.08.027_bb0100) 2014; 140 Clarke (10.1016/j.schres.2017.08.027_bb0025) 2009; 166 Gaspar (10.1016/j.schres.2017.08.027_bb0060) 2009; 111 Goldsmith (10.1016/j.schres.2017.08.027_bb0065) 2016; 21 Sekar (10.1016/j.schres.2017.08.027_bb0190) 2016; 530 Benros (10.1016/j.schres.2017.08.027_bb0010) 2014; 171 Marasco (10.1016/j.schres.2017.08.027_bb0115) 2014; 239 Pacifi (10.1016/j.schres.2017.08.027_bb0165) 2003; 289 Martin (10.1016/j.schres.2017.08.027_bb0120) 2004; 174 van Dijk (10.1016/j.schres.2017.08.027_bb0215) 2012; 137 Zalcman (10.1016/j.schres.2017.08.027_bb0225) 1999; 847 Zalcman (10.1016/j.schres.2017.08.027_bb0220) 1994; 643 Suarez-Pinilla (10.1016/j.schres.2017.08.027_bb0205) 2014; 40 Mori (10.1016/j.schres.2017.08.027_bb0145) 2015; 169 Pedraz (10.1016/j.schres.2017.08.027_bb0175) 2015; 6 Halpern (10.1016/j.schres.2017.08.027_bb0070) 2003; 88 Schizophrenia Working Group of the Psychiatric Genomics Consortium (10.1016/j.schres.2017.08.027_bb0185) 2014; 511 Frydecka (10.1016/j.schres.2017.08.027_bb0055) 2015; 262 Muller (10.1016/j.schres.2017.08.027_bb0150) 2004; 254 Laan (10.1016/j.schres.2017.08.027_bb0105) 2010; 71 Meyer (10.1016/j.schres.2017.08.027_bb0125) 2009; 66 O'Connor (10.1016/j.schres.2017.08.027_bb0160) 2009; 23 Nitta (10.1016/j.schres.2017.08.027_bb0155) 2013; 39 Swofford (10.1016/j.schres.2017.08.027_bb0210) 1996; 20 Keen (10.1016/j.schres.2017.08.027_bb0095) 2015; 20 Fernandez-Egea (10.1016/j.schres.2017.08.027_bb0035) 2013; 46 Levandowski (10.1016/j.schres.2017.08.027_bb0110) 2016; 628 Lieberman (10.1016/j.schres.2017.08.027_bb2015) 2005; 353 Shi (10.1016/j.schres.2017.08.027_bb0195) 2009; 460 Igue (10.1016/j.schres.2017.08.027_bb0075) 2011; 35 Keen (10.1016/j.schres.2017.08.027_bb0090) 2014; 20 Miller (10.1016/j.schres.2017.08.027_bb0135) 2011; 70 Miller (10.1016/j.schres.2017.08.027_bb0140) 2013; 39 Pae (10.1016/j.schres.2017.08.027_bb0170) 2006; 6 Araos (10.1016/j.schres.2017.08.027_bb0005) 2015; 20 Fox (10.1016/j.schres.2017.08.027_bb0045) 2012; 27 Miller (10.1016/j.schres.2017.08.027_bb0130) 2017; 42 |
| References_xml | – volume: 171 start-page: 218 year: 2014 end-page: 226 ident: bb0010 article-title: A Nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis publication-title: Am. J. Psychiatry contributor: fullname: Mortensen – volume: 71 start-page: 520 year: 2010 end-page: 527 ident: bb0105 article-title: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial publication-title: J. Clin. Psychiatry contributor: fullname: Selten – volume: 66 start-page: 1013 year: 2009 end-page: 1022 ident: bb0125 article-title: Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study publication-title: Biol. Psychiatry contributor: fullname: Lieberman – volume: 20 start-page: 756 year: 2015 end-page: 772 ident: bb0005 article-title: Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatients treatment: influence of cocaine symptom severity and psychiatric co-morbidity publication-title: Addict. Biol. contributor: fullname: Serrano – volume: 88 start-page: 1188 year: 2003 end-page: 1193 ident: bb0070 article-title: DiminishedInterleukin-6 response to proinflammatory challenge in men and women after intravenous cocaine administration publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Siegel – volume: 239 start-page: 1433 year: 2014 end-page: 1442 ident: bb0115 article-title: System-levels view of cocaine addiction: the interconnection of the immune and nervous systems publication-title: Exp. Biol. Med. contributor: fullname: Winder – volume: 289 start-page: 1929 year: 2003 end-page: 1930 ident: bb0165 article-title: Modulation of the immune system in Cannabis users publication-title: JAMA contributor: fullname: Pchini – volume: 40 start-page: 181 year: 2014 end-page: 191 ident: bb0200 article-title: Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update publication-title: Schizophr. Bull. contributor: fullname: Kahn – volume: 262 start-page: 449 year: 2015 end-page: 459 ident: bb0055 article-title: Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation publication-title: Eur. Arch. Psychiatry Clin. Neurosci. contributor: fullname: Sedlaczek – volume: 320 start-page: 507 year: 2007 end-page: 515 ident: bb0080 article-title: Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms publication-title: J. Pharmacol. Exp. Ther. contributor: fullname: Wang – volume: 31 start-page: 2033 year: 2006 end-page: 2046 ident: bb0085 article-title: Baseline neurocognitive deficits in the CATIE schizophrenia trial publication-title: Neuropsychopharmacology contributor: fullname: Lieberman – volume: 6 start-page: 666 year: 2006 end-page: 671 ident: bb0170 article-title: Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines publication-title: Int. Immunopharmacol. contributor: fullname: Paik – volume: 19 start-page: 209 year: 2016 end-page: 215 ident: bb0040 article-title: Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set publication-title: J. Affect. Disord. contributor: fullname: Brunel – volume: 530 start-page: 177 year: 2016 end-page: 183 ident: bb0190 article-title: Schizophrenia risk from complex variation of complement component 4 publication-title: Nature contributor: fullname: de Rivera – volume: 643 start-page: 40 year: 1994 end-page: 49 ident: bb0220 article-title: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6 publication-title: Brain Res. contributor: fullname: Murray – volume: 137 start-page: 50 year: 2012 end-page: 57 ident: bb0215 article-title: Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study publication-title: Schizophr. Res. contributor: fullname: van den Brink – volume: 151 start-page: 29 year: 2013 end-page: 35 ident: bb0030 article-title: Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway publication-title: Schizophr. Res. contributor: fullname: Yantis – volume: 254 start-page: 14 year: 2004 end-page: 22 ident: bb0150 article-title: COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy publication-title: Eur. Arch. Psychiatry Clin. Neurosci. contributor: fullname: Scheppach – volume: 628 start-page: 85 year: 2016 end-page: 90 ident: bb0110 article-title: Plasma interleukin-6 and executive function in crack cocaine-dependent women publication-title: Neurosci. Lett. contributor: fullname: Grassi-Oliveira – volume: 39 start-page: S242 year: 2013 end-page: S243 ident: bb0140 article-title: Interleukin-6 and cognition in non-affective psychosis publication-title: Schizophr. Bull. contributor: fullname: Buckley – volume: 167 start-page: 261 year: 2010 end-page: 280 ident: bb0015 article-title: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies publication-title: Am. J. Psychiatry contributor: fullname: Derkits – volume: 40 start-page: 269 year: 2014 end-page: 282 ident: bb0205 article-title: Immune system: a possible nexus between cannabinoid and psychosis publication-title: Brain Behav. Immun. contributor: fullname: Crespo-Facorro – volume: 35 start-page: 1695 year: 2011 end-page: 1698 ident: bb0075 article-title: Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry contributor: fullname: Kouassi – volume: 353 start-page: 1209 year: 2005 end-page: 1223 ident: bb2015 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. publication-title: N. Engl. J. Med. contributor: fullname: Perkins – volume: 16 start-page: 152 year: 2016 ident: bb0020 article-title: The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia publication-title: BMC Psychiatry contributor: fullname: Rosen – volume: 247 start-page: 228 year: 1997 end-page: 233 ident: bb0050 article-title: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission publication-title: Eur. Arch. Psychiatry Clin. Neurosci. contributor: fullname: Berger – volume: 140 start-page: 156 year: 2014 end-page: 160 ident: bb0100 article-title: Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans publication-title: Drug Alcohol Depend. contributor: fullname: Latimer – volume: 20 start-page: 145 year: 1996 end-page: 151 ident: bb0210 article-title: Substance use: a powerful predictor of relapse in schizophrenia publication-title: Schizophr. Res. contributor: fullname: Inderbitzin – volume: 847 start-page: 276 year: 1999 end-page: 283 ident: bb0225 article-title: Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats publication-title: Brain Res. contributor: fullname: Wise – volume: 42 start-page: 299 year: 2017 end-page: 317 ident: bb0130 article-title: Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future direction publication-title: Neuropsychopharmacology contributor: fullname: Goldsmith – volume: 27 start-page: 156 year: 2012 end-page: 166 ident: bb0045 article-title: Immune system inflammation in cocaine dependent individual: implications for medication development publication-title: Hum. Psychopharmacol. contributor: fullname: Kimmerling – volume: 20 start-page: 773 year: 2014 end-page: 783 ident: bb0090 article-title: Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults publication-title: J. Int. Neuropsychol. Soc. contributor: fullname: Turner – volume: 70 start-page: 663 year: 2011 end-page: 671 ident: bb0135 article-title: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects publication-title: Biol. Psychiatry contributor: fullname: Kirkpatrick – volume: 460 start-page: 753 year: 2009 end-page: 757 ident: bb0195 article-title: Common variants on chromosome 6p22.1 are associated with schizophrenia publication-title: Nature contributor: fullname: Duan – volume: 6 start-page: 1 year: 2015 end-page: 14 ident: bb0175 article-title: Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings publication-title: Front. Psych. contributor: fullname: Garcia-Marchena – volume: 23 start-page: 887 year: 2009 end-page: 897 ident: bb0160 article-title: To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers publication-title: Brain Behav. Immun. contributor: fullname: O'Connor – volume: 46 start-page: 25 year: 2013 end-page: 28 ident: bb0035 article-title: Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry contributor: fullname: Jones – volume: 169 start-page: 30 year: 2015 end-page: 35 ident: bb0145 article-title: Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study publication-title: Schizophr. Res. contributor: fullname: Miller – volume: 111 start-page: 891 year: 2009 end-page: 900 ident: bb0060 article-title: Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications publication-title: J. Neurochem. contributor: fullname: Silva – volume: 511 start-page: 421 year: 2014 end-page: 427 ident: bb0185 article-title: Biological insights from 108 schizophrenia-associated genetic loci publication-title: Nature contributor: fullname: Schizophrenia Working Group of the Psychiatric Genomics Consortium – volume: 21 start-page: 1696 year: 2016 end-page: 1709 ident: bb0065 article-title: Meta-analysis of cytokine alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression publication-title: Mol. Psychiatry contributor: fullname: Miller – volume: 20 start-page: 773 year: 2015 end-page: 783 ident: bb0095 article-title: Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults publication-title: J. Int. Neuropsychol. Soc. contributor: fullname: Turner – volume: 39 start-page: 1230 year: 2013 end-page: 1241 ident: bb0155 article-title: Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials publication-title: Schizophr. Bull. contributor: fullname: Kane – volume: 17 start-page: 2 year: 2013 end-page: 9 ident: bb0180 article-title: Factors associated with relapse in patients with schizophrenia publication-title: Int. J. Psychiatry Clin. Pract. contributor: fullname: Peña – volume: 174 start-page: 54 year: 2004 end-page: 64 ident: bb0120 article-title: Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia publication-title: Psychopharmacology (Berl) contributor: fullname: Freedman – volume: 166 start-page: 1025 year: 2009 end-page: 1030 ident: bb0025 article-title: Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia publication-title: Am. J. Psychiatry contributor: fullname: Cannon – volume: 27 start-page: 156 year: 2012 ident: 10.1016/j.schres.2017.08.027_bb0045 article-title: Immune system inflammation in cocaine dependent individual: implications for medication development publication-title: Hum. Psychopharmacol. doi: 10.1002/hup.1251 contributor: fullname: Fox – volume: 254 start-page: 14 year: 2004 ident: 10.1016/j.schres.2017.08.027_bb0150 article-title: COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy publication-title: Eur. Arch. Psychiatry Clin. Neurosci. doi: 10.1007/s00406-004-0478-1 contributor: fullname: Muller – volume: 20 start-page: 773 year: 2015 ident: 10.1016/j.schres.2017.08.027_bb0095 article-title: Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults publication-title: J. Int. Neuropsychol. Soc. doi: 10.1017/S1355617714000691 contributor: fullname: Keen – volume: 20 start-page: 773 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0090 article-title: Association between interleukin-6 and neurocognitive performance as a function of self-reported lifetime marijuana use in a community based sample of African American adults publication-title: J. Int. Neuropsychol. Soc. doi: 10.1017/S1355617714000691 contributor: fullname: Keen – volume: 23 start-page: 887 year: 2009 ident: 10.1016/j.schres.2017.08.027_bb0160 article-title: To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2009.04.005 contributor: fullname: O'Connor – volume: 88 start-page: 1188 issue: 3 year: 2003 ident: 10.1016/j.schres.2017.08.027_bb0070 article-title: DiminishedInterleukin-6 response to proinflammatory challenge in men and women after intravenous cocaine administration publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2002-020804 contributor: fullname: Halpern – volume: 19 start-page: 209 year: 2016 ident: 10.1016/j.schres.2017.08.027_bb0040 article-title: Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set publication-title: J. Affect. Disord. doi: 10.1016/j.jad.2015.11.017 contributor: fullname: Fond – volume: 20 start-page: 756 issue: 4 year: 2015 ident: 10.1016/j.schres.2017.08.027_bb0005 article-title: Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatients treatment: influence of cocaine symptom severity and psychiatric co-morbidity publication-title: Addict. Biol. doi: 10.1111/adb.12156 contributor: fullname: Araos – volume: 70 start-page: 663 year: 2011 ident: 10.1016/j.schres.2017.08.027_bb0135 article-title: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2011.04.013 contributor: fullname: Miller – volume: 21 start-page: 1696 year: 2016 ident: 10.1016/j.schres.2017.08.027_bb0065 article-title: Meta-analysis of cytokine alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression publication-title: Mol. Psychiatry doi: 10.1038/mp.2016.3 contributor: fullname: Goldsmith – volume: 39 start-page: S242 year: 2013 ident: 10.1016/j.schres.2017.08.027_bb0140 article-title: Interleukin-6 and cognition in non-affective psychosis publication-title: Schizophr. Bull. contributor: fullname: Miller – volume: 42 start-page: 299 year: 2017 ident: 10.1016/j.schres.2017.08.027_bb0130 article-title: Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future direction publication-title: Neuropsychopharmacology doi: 10.1038/npp.2016.211 contributor: fullname: Miller – volume: 289 start-page: 1929 issue: 15 year: 2003 ident: 10.1016/j.schres.2017.08.027_bb0165 article-title: Modulation of the immune system in Cannabis users publication-title: JAMA doi: 10.1001/jama.289.15.1929-a contributor: fullname: Pacifi – volume: 66 start-page: 1013 year: 2009 ident: 10.1016/j.schres.2017.08.027_bb0125 article-title: Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2009.06.005 contributor: fullname: Meyer – volume: 169 start-page: 30 year: 2015 ident: 10.1016/j.schres.2017.08.027_bb0145 article-title: Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study publication-title: Schizophr. Res. doi: 10.1016/j.schres.2015.10.001 contributor: fullname: Mori – volume: 6 start-page: 1 year: 2015 ident: 10.1016/j.schres.2017.08.027_bb0175 article-title: Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings publication-title: Front. Psych. contributor: fullname: Pedraz – volume: 511 start-page: 421 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0185 article-title: Biological insights from 108 schizophrenia-associated genetic loci publication-title: Nature doi: 10.1038/nature13595 contributor: fullname: Schizophrenia Working Group of the Psychiatric Genomics Consortium – volume: 628 start-page: 85 year: 2016 ident: 10.1016/j.schres.2017.08.027_bb0110 article-title: Plasma interleukin-6 and executive function in crack cocaine-dependent women publication-title: Neurosci. Lett. doi: 10.1016/j.neulet.2016.06.023 contributor: fullname: Levandowski – volume: 39 start-page: 1230 year: 2013 ident: 10.1016/j.schres.2017.08.027_bb0155 article-title: Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbt070 contributor: fullname: Nitta – volume: 320 start-page: 507 year: 2007 ident: 10.1016/j.schres.2017.08.027_bb0080 article-title: Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.106.112797 contributor: fullname: Irwin – volume: 247 start-page: 228 year: 1997 ident: 10.1016/j.schres.2017.08.027_bb0050 article-title: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission publication-title: Eur. Arch. Psychiatry Clin. Neurosci. doi: 10.1007/BF02900219 contributor: fullname: Frommberger – volume: 71 start-page: 520 year: 2010 ident: 10.1016/j.schres.2017.08.027_bb0105 article-title: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.09m05117yel contributor: fullname: Laan – volume: 31 start-page: 2033 issue: 9 year: 2006 ident: 10.1016/j.schres.2017.08.027_bb0085 article-title: Baseline neurocognitive deficits in the CATIE schizophrenia trial publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301072 contributor: fullname: Keefe – volume: 239 start-page: 1433 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0115 article-title: System-levels view of cocaine addiction: the interconnection of the immune and nervous systems publication-title: Exp. Biol. Med. doi: 10.1177/1535370214537747 contributor: fullname: Marasco – volume: 530 start-page: 177 issue: 7589 year: 2016 ident: 10.1016/j.schres.2017.08.027_bb0190 article-title: Schizophrenia risk from complex variation of complement component 4 publication-title: Nature doi: 10.1038/nature16549 contributor: fullname: Sekar – volume: 137 start-page: 50 issue: 1–3 year: 2012 ident: 10.1016/j.schres.2017.08.027_bb0215 article-title: Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study publication-title: Schizophr. Res. doi: 10.1016/j.schres.2012.01.016 contributor: fullname: van Dijk – volume: 643 start-page: 40 year: 1994 ident: 10.1016/j.schres.2017.08.027_bb0220 article-title: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6 publication-title: Brain Res. doi: 10.1016/0006-8993(94)90006-X contributor: fullname: Zalcman – volume: 166 start-page: 1025 year: 2009 ident: 10.1016/j.schres.2017.08.027_bb0025 article-title: Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2009.08010031 contributor: fullname: Clarke – volume: 40 start-page: 269 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0205 article-title: Immune system: a possible nexus between cannabinoid and psychosis publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2014.01.018 contributor: fullname: Suarez-Pinilla – volume: 6 start-page: 666 year: 2006 ident: 10.1016/j.schres.2017.08.027_bb0170 article-title: Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2005.10.004 contributor: fullname: Pae – volume: 847 start-page: 276 year: 1999 ident: 10.1016/j.schres.2017.08.027_bb0225 article-title: Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats publication-title: Brain Res. doi: 10.1016/S0006-8993(99)02063-6 contributor: fullname: Zalcman – volume: 46 start-page: 25 year: 2013 ident: 10.1016/j.schres.2017.08.027_bb0035 article-title: Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2013.06.011 contributor: fullname: Fernandez-Egea – volume: 35 start-page: 1695 year: 2011 ident: 10.1016/j.schres.2017.08.027_bb0075 article-title: Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2011.05.011 contributor: fullname: Igue – volume: 17 start-page: 2 issue: 1 year: 2013 ident: 10.1016/j.schres.2017.08.027_bb0180 article-title: Factors associated with relapse in patients with schizophrenia publication-title: Int. J. Psychiatry Clin. Pract. doi: 10.3109/13651501.2012.687452 contributor: fullname: San – volume: 151 start-page: 29 year: 2013 ident: 10.1016/j.schres.2017.08.027_bb0030 article-title: Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway publication-title: Schizophr. Res. doi: 10.1016/j.schres.2013.10.019 contributor: fullname: Dimitrov – volume: 140 start-page: 156 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0100 article-title: Self-reported lifetime marijuana use and interleukin-6 levels in middle-aged African Americans publication-title: Drug Alcohol Depend. doi: 10.1016/j.drugalcdep.2014.04.011 contributor: fullname: Keen – volume: 20 start-page: 145 issue: 1–2 year: 1996 ident: 10.1016/j.schres.2017.08.027_bb0210 article-title: Substance use: a powerful predictor of relapse in schizophrenia publication-title: Schizophr. Res. doi: 10.1016/0920-9964(95)00068-2 contributor: fullname: Swofford – volume: 171 start-page: 218 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0010 article-title: A Nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2013.13010086 contributor: fullname: Benros – volume: 167 start-page: 261 year: 2010 ident: 10.1016/j.schres.2017.08.027_bb0015 article-title: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2009.09030361 contributor: fullname: Brown – volume: 16 start-page: 152 year: 2016 ident: 10.1016/j.schres.2017.08.027_bb0020 article-title: The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia publication-title: BMC Psychiatry doi: 10.1186/s12888-016-0866-x contributor: fullname: Chase – volume: 353 start-page: 1209 year: 2005 ident: 10.1016/j.schres.2017.08.027_bb2015 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa051688 contributor: fullname: Lieberman – volume: 111 start-page: 891 year: 2009 ident: 10.1016/j.schres.2017.08.027_bb0060 article-title: Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications publication-title: J. Neurochem. doi: 10.1111/j.1471-4159.2009.06325.x contributor: fullname: Gaspar – volume: 174 start-page: 54 year: 2004 ident: 10.1016/j.schres.2017.08.027_bb0120 article-title: Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-003-1750-1 contributor: fullname: Martin – volume: 262 start-page: 449 issue: 6 year: 2015 ident: 10.1016/j.schres.2017.08.027_bb0055 article-title: Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation publication-title: Eur. Arch. Psychiatry Clin. Neurosci. contributor: fullname: Frydecka – volume: 460 start-page: 753 year: 2009 ident: 10.1016/j.schres.2017.08.027_bb0195 article-title: Common variants on chromosome 6p22.1 are associated with schizophrenia publication-title: Nature doi: 10.1038/nature08192 contributor: fullname: Shi – volume: 40 start-page: 181 year: 2014 ident: 10.1016/j.schres.2017.08.027_bb0200 article-title: Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbt139 contributor: fullname: Sommer |
| SSID | ssj0001507 |
| Score | 2.428272 |
| Snippet | Schizophrenia has been associated with aberrant blood levels of inflammatory markers. However, patients with comorbid illicit drug use have been inadequately... INTRODUCTIONSchizophrenia has been associated with aberrant blood levels of inflammatory markers. However, patients with comorbid illicit drug use have been... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 275 |
| SubjectTerms | Cocaine Cognition Inflammation Marijuana Psychopathology Schizophrenia |
| Title | Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study |
| URI | https://dx.doi.org/10.1016/j.schres.2017.08.027 https://www.ncbi.nlm.nih.gov/pubmed/28843438 https://search.proquest.com/docview/1933230692 |
| Volume | 195 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB3BcukFgVrKlhYZqccNm8T5cI4rBFqKxKVF4mbFXyIcsis2e-1f4C8zYzuolVohcUwUK1Zm8vzGnjcD8J2rtGoR9xNbaNq6EVmiMoxS0to4LVrnMuOrfd5Wy7vix315vwMXoxaG0ioj9gdM92gd78zj15yvu27-M21I9lkVGTppib66C3v-kGgCe4vrm-XtKyAT5_El93AONGBU0Pk0L4whMa6lHK_a1_Kk9jL_XqH-x0D9SnR1APuRQrJFmOUh7Nj-Izxf9w6NG4SIM7ZBPBjIoGy7sTMWtFbUfdjvos9Y2xsWM4dWPet6tn7A5YxlbOUYUkI2CibxwaGLSq1OM9_jY0MPdX_kSrKQFBJxk_mKtZ_g7ury18Uyic0WEo0RyJDopm65crrkFYl1VWaFbk2jkR4648q8yamVpymFylVdp6lDZuGMyYSuLK9UxY9g0q96ewzMUcWehqNvKFPomlOJwLLgqbFKoF_YKSTjB5brUFNDjslmjzIYRJJBJHXIzOsp1KMV5F--IRH23xh5NhpN4m9DZyFtb1fbjUTeyin6avIpfA7WfJ1LLgTpbcWXd7_3BD7glQiJkV9hMjxt7TckL4M6hd3z39lpdNEXLpnxog |
| link.rule.ids | 315,783,787,4511,24130,27938,27939,45599,45693 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELZ4HOCCWC0LBXbxShwbNYnzcI4IUbXA9rKt1JsVv0T2kFY0_R38ZWZsBy0SK6S9JrFieSafv3HmmyHkmsm4qAH3I5MpPLrhSSQTiFLiUlvFa2sT7ap9zorJIrtf5ssdcttrYTCtMmC_x3SH1uHKKKzmaN00o99xhbLPIkvASXPw1V2yD2ygAmffv5k-TGZvgIycx5XcgznggF5B59K8IIaEuBZzvEpXyxPby3y8Q_2LgbqdaHxMjgKFpDd-ll_Ijmm_kpdpa8G4Xog4pBvAgw4NSrcbM6Rea4Xdh90p-pDWraYhc2jV0qal6yfYzmhCV5YCJaS9YBIe7Jqg1GoUdT0-NvhQ81euJPVJIQE3qatYe0IW47v57SQKzRYiBRFIF6mqrJm0KmcFinVlYriqdaWAHlpt87RKsZWnzrlMZVnGsQVmYbVOuCoMK2TBvpG9dtWaM0ItVuypGPiG1JkqGZYIzDMWayM5-IUZkKhfYLH2NTVEn2z2R3iDCDSIwA6ZaTkgZW8F8c43BMD-JyN_9kYT8Nngv5C6NavtRgBvZRh9VemAnHprvs0l5Rz1tvz8v997RQ4m81-P4nE6e7ggh3CH-yTJS7LXPW_NdyAynfwRHPUVH3Pznw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammation%2C+substance+use%2C+psychopathology%2C+and+cognition+in+phase+1+of+the+clinical+antipsychotic+trials+of+intervention+effectiveness+study&rft.jtitle=Schizophrenia+research&rft.au=Miller%2C+Brian+J&rft.au=Buckley%2C+Peter+F&rft.au=McEvoy%2C+Joseph+P&rft.date=2018-05-01&rft.eissn=1573-2509&rft.volume=195&rft.spage=275&rft_id=info:doi/10.1016%2Fj.schres.2017.08.027&rft_id=info%3Apmid%2F28843438&rft.externalDocID=28843438 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-9964&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-9964&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-9964&client=summon |